Andrea Olarte-San Juan

Concomitant ablation of SOS1 and SOS2 triggers a lethal phenotype involving compromised intestinal integrity and widespread septicemia

This study shows that deleting both SOS1 and SOS2 in mice causes intestinal damage, bacterial leakage, and septicemia, but stemness-enhancing therapies improve survival.

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors

This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.